[go: up one dir, main page]

WO2003031411A3 - Dedoublement direct de chlorhydrate de threo-methylphenidate racemique - Google Patents

Dedoublement direct de chlorhydrate de threo-methylphenidate racemique Download PDF

Info

Publication number
WO2003031411A3
WO2003031411A3 PCT/US2002/032658 US0232658W WO03031411A3 WO 2003031411 A3 WO2003031411 A3 WO 2003031411A3 US 0232658 W US0232658 W US 0232658W WO 03031411 A3 WO03031411 A3 WO 03031411A3
Authority
WO
WIPO (PCT)
Prior art keywords
direct resolution
methylphenidate hydrochloride
racemic threo
threo
methylphenidate
Prior art date
Application number
PCT/US2002/032658
Other languages
English (en)
Other versions
WO2003031411A2 (fr
Inventor
Jeroen Verheijen
Shoucheng Du
Mel H Epstein
Original Assignee
Sention Inc
Jeroen Verheijen
Shoucheng Du
Mel H Epstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sention Inc, Jeroen Verheijen, Shoucheng Du, Mel H Epstein filed Critical Sention Inc
Priority to AU2002353803A priority Critical patent/AU2002353803A1/en
Publication of WO2003031411A2 publication Critical patent/WO2003031411A2/fr
Publication of WO2003031411A3 publication Critical patent/WO2003031411A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé pour effectuer le dédoublement direct de thréo-méthylphénidate racémique. Ledit procédé consiste à : former un sel diastéréomérique de thréo-méthylphénidate et un énantiomère unique d'acide di-p-toluoyltartarique ; et cristalliser un des diastéréomères. Le diastéréomère ainsi formé peut être facilement transformé en tout autre sel pharmaceutiquement acceptable.
PCT/US2002/032658 2001-10-12 2002-10-11 Dedoublement direct de chlorhydrate de threo-methylphenidate racemique WO2003031411A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002353803A AU2002353803A1 (en) 2001-10-12 2002-10-11 Direct resolution of racemic threo-methylphenidate hydrochloride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32872201P 2001-10-12 2001-10-12
US60/328,722 2001-10-12

Publications (2)

Publication Number Publication Date
WO2003031411A2 WO2003031411A2 (fr) 2003-04-17
WO2003031411A3 true WO2003031411A3 (fr) 2003-07-24

Family

ID=23282136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/032658 WO2003031411A2 (fr) 2001-10-12 2002-10-11 Dedoublement direct de chlorhydrate de threo-methylphenidate racemique

Country Status (2)

Country Link
AU (1) AU2002353803A1 (fr)
WO (1) WO2003031411A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897777B2 (en) * 2007-01-05 2011-03-01 Archimica, Inc. Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate
WO2015069505A1 (fr) * 2013-11-08 2015-05-14 Noramco, Inc. Procédé de préparation de méthylphénidate et de ses sels pharmaceutiques
CN110878021A (zh) * 2019-12-05 2020-03-13 济南大学 一种酒石酸衍生物的制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027176A1 (fr) * 1996-01-22 1997-07-31 Medeva Europe Limited Resolution optique de methylphenidate par des acides 0,0'-bisaryoltartariques
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027176A1 (fr) * 1996-01-22 1997-07-31 Medeva Europe Limited Resolution optique de methylphenidate par des acides 0,0'-bisaryoltartariques
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride

Also Published As

Publication number Publication date
AU2002353803A1 (en) 2003-04-22
WO2003031411A2 (fr) 2003-04-17

Similar Documents

Publication Publication Date Title
FR2841264B1 (fr) PROCEDE DE PREPARATION D'UN ALLIAGE AI-Zn-Mg-Cu A HAUTE RESISTANCE
IL166768A (en) 2-oxo-1-pyrrolidine derivatives and a process for their preparation
EG24849A (en) Method for the production of crystalline forms andcrystalline forms of optical enantiomers of modaf inil
HUP0402590A3 (en) Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
CA2307391A1 (fr) Un procede de preparation d'herbicides d'imidazolinones chirales
WO2002066429A8 (fr) Procede de production d'hydrochlorure fexofenadine non hydrate et nouvelle forme cristalline ainsi obtenue
WO2003031411A3 (fr) Dedoublement direct de chlorhydrate de threo-methylphenidate racemique
CA2431400A1 (fr) Procede de preparation d'isomeres de salbutamol
WO2001023346A3 (fr) Procedes de production de produits derives d'acides phenylacetiques
AU2002367268A1 (en) Processes for production of cyclic diamine compounds or salts thereof
WO2007009143A3 (fr) Procede de production de nebivolol
WO2001098265A3 (fr) Procede d'obtention d'enantiomeres de cetamine racemique, procede d'obtention de sels pharmaceutiquement acceptables a partir d'enantiomeres de cetamine racemique et utilisation de sels pharmaceutiquement acceptables obtenus au moyen dudit procede mentionne
FR2824892B1 (fr) Procede de fabrication d'un reservoir haute pression notamment pour lanceur spatial et reservoir obtenu
NO20053368D0 (no) Fremgangsmate for fremstilling av en farmasoytisk ren polymorf I av olanzapin.
AU2002229706A1 (en) Process for the fermentative production of d-pantothenic acid
WO2005056563A3 (fr) Procedes
PH12005500143B1 (en) Microbiological method for the production of 7 alpha-substituted 11 alpha-hydroxysteroids
EP1580191A4 (fr) Procede de production d'un compose de carbapenem pour l'administration par voie orale
CA2487036A1 (fr) Procede de fabrication de composes phorphordiamidites
FR2827294B1 (fr) Procede discontinu de fabrication d'un polyamide
EE200400016A (et) Protsess 1,5-diarüül-3-trifluorometüül-delta²-pürasoliinide ratseemiliste ja enantiomeerselt puhaste derivaatide valmistamiseks
AU2002352423A8 (en) Process for the manufacture of pharmaceutically acceptable salts of a compound
IL164437A0 (en) Method for the production of 2,4,5-trimethylphenylacetic acid
GB0021147D0 (en) Chemical process
HUP0402558A3 (en) Process for production of 3,3-dimethyl-2-formylcyclopropanecarboxylic acid derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP